Literature DB >> 10685922

Wechsler subscale IQ and subtest profile in early treated phenylketonuria.

P V Griffiths1, C Demellweek, N Fay, P H Robinson, D C Davidson.   

Abstract

AIM: Mildly depressed IQ is common in treated phenylketonuria. This study explored whether a particular intellectual ability profile typifies early and continuously treated phenylketonuria and whether component skills comprising the IQ relate to socioeconomic and treatment factors.
METHODS: IQ scores were collected retrospectively from variants of the "Wechsler intelligence scale for children" performed at age 8 on 57 children with early treated, classic phenylketonuria. The mental ability pattern underlying IQ was investigated by analysing subscale and subtest scores and dietary factors, such as historical phenylalanine blood concentrations.
RESULTS: The children's mean full scale IQ of 91.11 was significantly below the healthy population norm. There was a significant discrepancy between their mean verbal IQ (94.65) and mean performance IQ (89.42), suggestive of a spatial deficit, but the data did not support a biochemical or sociological explanation. Individual Wechsler subtests had no distinctive pattern. Phenylalanine control at age 2 was predictive of overall IQ. At this age, children with annual median phenylalanine < 360 micromol/litre (recommended UK upper limit) had a mean IQ 10 points higher than those above.
CONCLUSIONS: Early and continuous treatment of phenylketonuria does not necessarily lead to normalisation of overall IQ. Verbal intelligence in the primary school years appears to normalise if blood phenylalanine is maintained below 360 micromol/litre in infancy, but spatial intelligence may remain poor. However, the discrepancy in skill development is not the result of social status or treatment variables. Perhaps weak spatial intelligence is an ancillary effect of a protective rearing style occasioned by the dietary treatment regimen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10685922      PMCID: PMC1718264          DOI: 10.1136/adc.82.3.209

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  23 in total

1.  The limping child: epidemiology, assessment and outcome.

Authors:  S U Fischer; T F Beattie
Journal:  J Bone Joint Surg Br       Date:  1999-11

2.  Intelligence and behaviour in children with early treated phenylketonuria. A report from the MRC/DHSS phenylketonuria register.

Authors:  I Smith; M Beasley
Journal:  Eur J Clin Nutr       Date:  1989       Impact factor: 4.016

3.  Perceptual-motor functioning in children with phenylketonuria.

Authors:  E Koff; P Boyle; S M Pueschel
Journal:  Am J Dis Child       Date:  1977-10

4.  Psychosocial aspects in phenylketonuria.

Authors:  J Weglage; B Fünders; K Ullrich; A Rupp; E Schmidt
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

5.  Phenylketonuria and complex spatial visualization: an analysis of information processing.

Authors:  R L Brunner; D B Berch; H Berry
Journal:  Dev Med Child Neurol       Date:  1987-08       Impact factor: 5.449

6.  Correlates of intelligence test results in treated phenylketonuric children.

Authors:  M L Williamson; R Koch; C Azen; C Chang
Journal:  Pediatrics       Date:  1981-08       Impact factor: 7.124

Review 7.  Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood.

Authors:  F Güttler
Journal:  Acta Paediatr Scand Suppl       Date:  1980

8.  Neuropsychological deficits in early treated phenylketonuric children.

Authors:  B F Pennington; W J van Doorninck; L L McCabe; E R McCabe
Journal:  Am J Ment Defic       Date:  1985-03

9.  Intellectual assessment of 111 four-year-old children with phenylketonuria.

Authors:  J C Dobson; M L Williamson; C Azen; R Koch
Journal:  Pediatrics       Date:  1977-12       Impact factor: 7.124

10.  Intellectual development and academic achievement of children treated early for phenylketonuria.

Authors:  H K Berry; D J O'Grady; L J Perlmutter; M K Bofinger
Journal:  Dev Med Child Neurol       Date:  1979-06       Impact factor: 5.449

View more
  8 in total

1.  Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Authors:  Emma Medford; Dougal Julian Hare; Anja Wittkowski
Journal:  JIMD Rep       Date:  2017-08-25

2.  Transition of young adults with phenylketonuria from pediatric to adult care.

Authors:  Ulrike Mütze; Annika Roth; Johannes F W Weigel; Skadi Beblo; Christoph G Baerwald; Peter Bührdel; Wieland Kiess
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

3.  Family conditions and dietary control in phenylketonuria.

Authors:  G M Olsson; S M Montgomery; J Alm
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

4.  Cognitive functioning and psychiatric disorders in children with a metabolic disease.

Authors:  Annik Simons; François Eyskens; Ann De Groof; Ellen Van Diest; Dirk Deboutte; Robert Vermeiren
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-03-10       Impact factor: 4.785

5.  Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis.

Authors:  Christopher J Fonnesbeck; Melissa L McPheeters; Shanthi Krishnaswami; Mary Louise Lindegren; Tyler Reimschisel
Journal:  J Inherit Metab Dis       Date:  2012-11-30       Impact factor: 4.982

6.  Treatment adherence during childhood in individuals with phenylketonuria: Early signs of treatment discontinuation.

Authors:  María Ignacia García; Gabriela Araya; Soledad Coo; Susan E Waisbren; Alicia de la Parra
Journal:  Mol Genet Metab Rep       Date:  2017-04-28

7.  Cognitive functioning in mild hyperphenylalaninemia.

Authors:  Alicia de la Parra; María Ignacia García; Susan E Waisbren; Verónica Cornejo; Erna Raimann
Journal:  Mol Genet Metab Rep       Date:  2015-10-29

8.  First-year metabolic control guidelines and their impact on future metabolic control and neurocognitive functioning in children with PKU.

Authors:  Alicia de la Parra; María Ignacia García; Valerie Hamilton; Carolina Arias; Juan Francisco Cabello; Verónica Cornejo
Journal:  Mol Genet Metab Rep       Date:  2017-10-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.